Current Report Filing (8-k)
November 28 2016 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
FORM 8-K
___________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: November 28, 2016
(
Date of earliest event reported
)
CELLECTAR BIOSCIENCES, INC.
(
Exact name of registrant as specified in its charter
)
Delaware
|
1-36598
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification Number)
|
3301 Agriculture Drive
Madison, WI 53716
(
Address of principal executive offices
)
(608) 441-8120
(
Registrant's telephone number, including area code
)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 7.01 REGULATION FD DISCLOSURE
On November 28, 2016, we issued a press release announcing
that we have selected Hamilton, Ontario-based Centre for Probe Development and Commercialization (CPDC), a well-respected GMP
manufacturing organization specializing in radiopharmaceuticals, as a supplier of the company’s lead phospholipid drug conjugate,
CLR 131. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Number
|
|
Title
|
99.1
|
|
Press release dated November 28, 2016, entitled “Cellectar Biosciences Announces Partnership with Radiopharmaceutical Specialists, CPDC, to Establish Manufacturing Capacity in Anticipation of CLR 131 Pivotal Trial and Commercial Production”
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 28, 2016
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Chad J. Kolean
|
|
|
Name: Chad J. Kolean
|
|
|
Title: Vice President and Chief Financial Officer
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2024 to May 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From May 2023 to May 2024